KR100873819B1 - 근육 손상의 처치방법 - Google Patents
근육 손상의 처치방법 Download PDFInfo
- Publication number
- KR100873819B1 KR100873819B1 KR1020037004676A KR20037004676A KR100873819B1 KR 100873819 B1 KR100873819 B1 KR 100873819B1 KR 1020037004676 A KR1020037004676 A KR 1020037004676A KR 20037004676 A KR20037004676 A KR 20037004676A KR 100873819 B1 KR100873819 B1 KR 100873819B1
- Authority
- KR
- South Korea
- Prior art keywords
- muscle
- botulinum toxin
- bont
- injured
- neurotoxin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
화합물 | NMJ와 관련된 작용부위 | 약제학적 분류 |
아세틸콜린 에스테라아제 유도인자 아코니틴 아데노레굴린 (개구리 필로메데우사 비칼라에서 유래) 아데노신 작용물질 아데노신 길항제 아데노신 조절제 아드레날린제 아나톡신-A 항간질제 | 시냅스 시냅스전 시냅스전 시냅스 전 및 후 시냅스 전 및 후 시냅스 전 및 후 시냅스전 시냅스후 CNS | ACh 에스테아라제 유도인자 나트륨 채널 활성화제 아데노신 수용체 조절인자 아데노신 아데노신 아데노신 알파 아드레날린제 Ach 작용물질 항간질제 |
안티센스 항불안제 아타쿠리움 아트라쿠리움 베실레이트 (Tracurium) 바크로펜 (Lioresal.RTM., Intrathecal, Medtronic Neurological; generic, Athena, Biocrage, Watner Chilcott) 박테리아, 식물 및 균류 생성물 바트라코톡신 벤질피페리딘류 식물성 신경독 붕가로톡신-β (β-BuTX) 부피바카인 카프토프릴 (Captopen .RTM., Squibb; Capzide .RTM., (Squibb) 콜린+아세틸 트렌스페라아제 억제제 콜린에스테라아제 억제제 시구아톡신류 코노톡신 MI (알파 코노톡신) | 시냅스 전 및 후 CNS 시냅스후 시냅스후 시냅스전 시냅스전 시냅스 간극 전 및 후 시냅스 및 시냅스 간극 시냅스전 시냅스 전 및 후 시냅스전 시냅스전 시냅스 간극 시냅스전 시냅스후 | 특이적인 단백질 또는 신경전달 방출에 중요한 메세지, 수용체 생성을 위한 안티센스 기술 항불안제 항간질제 AchR 길항제 비탈분극 근육 이완제 AchR 길항제 비탈분극 근육 이완제 GABA 유사물질 나트륨 채널 활성화제 Ach 에스테라아제 억제제 (비전통적) 다양 PLA2 및 전압 민감성 칼륨 채널 차단제 붕가루스 멀티싱크투스로부터 유래한 뱀 독 국소 마취제 미오톡신 항고혈압제 ACE 억제제 아연 엔도펩티다아제 억제제 CAT 억제제 Ach 에스테라아제 억제제 나트륨 채널 AChR 길항제 |
코노톡신-.mu. GIIIA (mu-CT) 코노톡신-.OMEGA. GVIA (omega-CT) 큐라레 댄크롤렌 소디움 (Dantrium, P&G) 다우리신 데카메토니움 브로마이드 덴드로톡신 디아미노피리딘 (3-DAP) 디아제팜 독사쿠리움 클로라이드 (Nuromax .RTM., Burroughs Wellcome) 독소루비신 (Adriamyocin, Adria; Rubex, Immunex; Cetus Onoclogy) 에피바티딘 디하이드로클로라이드 휄바메이트 (Felvatol, Carter- CNS Wallace lic to Schering-Plough) 호록시미틴 가바펜틴 (Neurontin, Parke- Davis) 갈라민 그레이안톡신 헥사하이드로아제피닐 아세트아미드류 및 다른 화학 분류 후페르진 A 곤충 독 이온 채널 차단제 이온 채널 자극제 | 시냅스후 시냅스후 시냅스후 시냅스전 시냅스 전 및 후 시냅스전 CNS 시냅스후 시냅스후 시냅스후 시냅스전 시냅스전 시냅스전 CNS 시냅스후 시냅스전 시냅스전 시냅스 간극 시냅스 전 및 후 시냅스 전 및 후 | Na+ 채널 차단제 Ca2+ 채널 차단제 뉴트론에서만 AChR 길항제 비탈분극 골격근 이완제 AChR 길항제 신경절 차단제 칼륨 채널 차단제 보툴리눔 독소 중독 복귀 항불안제 AChR 길항제 탈분극 근육 이완제 미오톡신 화학적 근부분절제술 AChR 작용물질 항간질제 안지오텐신 I 전환 효소 억제제 항간질제 GABA 유사물질 AChR 길항제 나트륨 채널 활성화제 Ach 방출제 ACh 에스테라아제 억제제 채널 차단제 채널 자극제 |
라트로톡신-α 리도카인, 프로카인, 메피바카인, 등 리노피르딘 (Dup 996, Dupont Merck) 로포톡신 및 유사물질 해양 천연 생성물 메토카르바몰 (Rabaxin, Robins Co.) 메틸리카코니틴 미바쿠리움 클로라이드 (Mivacro .RTM., BW- BW1090U, Burroughs Wellcome) 변형된 클로스트리디움계 독소류 단클론성 NMJ 컴포넌트에 대한 항체 무스카린성 작용물질 및 길항제 네오삭시톡신 네오수루가톡신 신경근 차단제 파충류, 곤충, 및 다른 소스로부터의 신경독 판쿠로니움 브로마이드 (organon) 판쿠로니움-3-OH 대사산물 (organon) | 시냅스전 시냅스전 시냅스전 시냅스후 시냅스후 시냅스전 시냅스 전 및 후 시냅스전 시냅스후 시냅스 전 및 후 및 시냅스 간극 시냅스후 시냅스후 | 칼슘 이온운반체 블랙 위도우 거미 독 컴포넌트 국소마취제 ACh 방출 강화제 AChR 길항제 비가역적 CNS 억압, 근육 이완제 AChR 길항제 비탈분극 근육 이완제 ACh 방출 억제제 수용체, 아그린, 신경전달물질, 원형질막 구성성분, 효소 비활성화 등. 무스카린성제 CNS 작용물질 길항제 나트륨 채널 차단제 자율신경계 신경절 AChR 차단제 (NMJ에서는 효과없음) AchR 길항제 AChR 분극화 다양 AChR 길항제 비탈분극 근육 이완제 AChR 길항제 비탈분극 근육 이완제 |
팝베린 HCl (30mg/ml) 피소스티그민 및 유사물질 피페르쿠로니움 (Arduan, Organon) 시냅스전 신경 말단 수용체 단기 신경독 알파 β-붕가로톡신 (β-BuTX) 숙시닐콜린 클로라이드 (Anectine, Burroughs Wellcome) 테타니 독소 테나니 독소 운반체 테트라하이드로아미노- 아크리딘(THA) 테트로도톡신 티아가빈 (Novo Nordisk) 트랜스글루타미나아제 억제제 또는 유도 방지 발리움 베쿠로니움 (Norcuron, Organon) 베쿠로니움-3-OH 대사산물 (organon) 베라트리딘 비가바트린 (Sabril, Marion Merrell Dow) 베사미콜 및 동일 메카니즘의 다른 약물 아연 엔도펩티다아제 및 보툴리눔 독소 또는 테타니 독소 운반체에서 유래하는 다른 프로테아제 | 시냅스 간극 시냅스후 시냅스전 시냅스후 시냅스전 시냅스후 시냅스전 시냅스전 시냅스 간극 시냅스 전 및 후 CNS 시냅스 전 및 후 시냅스후 시냅스후 시냅스전 시냅스전 CNS 시냅스전 시냅스전 | 평활근 이완제 ACh 에스테라아제 억제제 AChR 길항제 비탈분극 근육 이완제 신경말단의 뉴런외 또는 뉴런간 수용체 AChR 길항제 붕가루스 멀티싱크투스로부터 유래한 뱀 독 AChR 수용체 작용물질 탈분극 골격근 이완제 EAA 방출 억제제 Ach 에스테라아제 억제제 나트륨 채널 차단제 항간질제 GABA 흡수 억제제 효소 디아제팜 CNS 항불안제 AChR 길항제 비탈분극 근육 이완제 AChR 길항제 비탈분극 근육 이완제 나트륨 채널 활성화제 항간질제 GABA 대사 억제제 (비가역적) ACh 소포 수송 억제제 효소 신경전달물질 방출 감소 |
Claims (13)
- 타박상, 열상, 국소빈혈, 좌상(strain) 및 완전 파열을 포함하는 손상 근육에서 2 내지 4개월간 근육 고정을 나타내는 보툴리눔 독소를 포함하는 손상 근육 치료용 약학 조성물.
- 제 1 항에 있어서,상기 보툴리눔 독소가 근육내 주사가 가능한 것임을 특징으로 하는 손상 근육 치료용 약학 조성물.
- 삭제
- 제 1 항에 있어서,상기 보툴리눔 독소가 상기 손상 근육의 회복 프로세스의 제 1 단계인 파괴단계 및 제 2 단계인 회복단계 동안 상기 손상 근육을 고정하는데 효과적인 것을 특징으로 하는 손상 근육 치료용 약학 조성물.
- 제 1 항에 있어서,상기 보툴리눔 독소가 상기 손상 근육의 회복 프로세스의 제 1 단계인 파괴단계 동안 상기 손상 근육을 고정하는데 효과적인 것을 특징으로 하는 손상 근육 치료용 약학 조성물.
- 제 1 항에 있어서,상기 보툴리눔 독소가 보툴리눔 독소 타입 A, B, C 1 , D, E, F 또는 G인 것을 특징으로 하는 손상 근육 치료용 약학 조성물.
- 제 1 항에 있어서,상기 보툴리눔 독소가 재조합적으로 제조된 보툴리눔 독소임을 특징으로 하는 손상 근육 치료용 약학 조성물.
- 제 1 항에 있어서,상기 보툴리눔 독소가 물리 치료, 외과 수술 또는 물리 치료와 외과수술의 조합의 전 또는 후에 투여가능한 것임을 특징으로 하는 손상 근육 치료용 약학 조성물.
- in vivo 국소 투여 가능한 제형의 보툴리눔 독소를 포함하는 손상 근육 치료용 약학 조성물.
- 제 9 항에 있어서,상기 보툴리눔 독소가 보툴리눔 독소 타입 A임을 특징으로 하는 손상 근육 치료용 약학 조성물.
- 타박상, 열상, 국소빈혈, 좌상(strain) 및 완전 파열을 포함하는 손상 근육의 치유를 촉진하는 in vivo 국소 투여 가능한 제형의 보툴리눔 독소 타입 A를 포함하는 손상 근육 치유 촉진용 약학 조성물.
- 삭제
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/678,189 US6423319B1 (en) | 2000-10-04 | 2000-10-04 | Methods for treating muscle injuries |
US09/678,189 | 2000-10-04 | ||
PCT/US2001/027193 WO2002028425A2 (en) | 2000-10-04 | 2001-08-31 | Methods for treating muscle injuries |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030043981A KR20030043981A (ko) | 2003-06-02 |
KR100873819B1 true KR100873819B1 (ko) | 2008-12-11 |
Family
ID=24721759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037004676A KR100873819B1 (ko) | 2000-10-04 | 2001-08-31 | 근육 손상의 처치방법 |
Country Status (16)
Country | Link |
---|---|
US (4) | US6423319B1 (ko) |
EP (2) | EP2174662A3 (ko) |
JP (2) | JP2004518632A (ko) |
KR (1) | KR100873819B1 (ko) |
CN (2) | CN1658897A (ko) |
AT (1) | ATE477816T1 (ko) |
AU (2) | AU8699101A (ko) |
BR (1) | BR0114440A (ko) |
CA (1) | CA2424242C (ko) |
DE (1) | DE60142839D1 (ko) |
DK (1) | DK1322324T3 (ko) |
ES (1) | ES2348862T3 (ko) |
MX (1) | MXPA03002576A (ko) |
NZ (1) | NZ524793A (ko) |
TW (1) | TWI292713B (ko) |
WO (1) | WO2002028425A2 (ko) |
Families Citing this family (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060216313A1 (en) * | 1999-08-10 | 2006-09-28 | Allergan, Inc. | Methods for treating a stricture with a botulinum toxin |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US20040170665A1 (en) * | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US7691983B2 (en) * | 2000-07-21 | 2010-04-06 | Allergan, Inc. | Chimera botulinum toxin type E |
US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US20040219619A1 (en) * | 2000-07-21 | 2004-11-04 | Ester Fernandez-Salas | Methods of identifying compounds that alter toxin persistence and/or protease activity |
US7491799B2 (en) * | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
US6423319B1 (en) * | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
ITUD20010002A1 (it) * | 2001-01-05 | 2002-07-05 | Univ Degli Studi Udine | Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo |
JP4707254B2 (ja) * | 2001-04-24 | 2011-06-22 | クミアイ化学工業株式会社 | 粒状組成物及びその製造方法 |
US20020197278A1 (en) * | 2001-06-21 | 2002-12-26 | Surromed, Inc. | Covalent coupling of botulinum toxin with polyethylene glycol |
CN1585642A (zh) * | 2001-11-15 | 2005-02-23 | 微观藻类公司 | 包含3,4-丙炔基全氢化嘌呤的药物组合物及其在阻滞神经元传递方面的应用 |
US7140371B2 (en) * | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
US7300412B2 (en) * | 2002-05-10 | 2007-11-27 | Hospital For Joint Diseases | Methods for therapeutic treatment of carpal tunnel syndrome |
WO2004012674A2 (en) * | 2002-08-02 | 2004-02-12 | Nutraceutical Development Corporation | Development of muscle mass in a mammal |
US20040037895A1 (en) * | 2002-08-23 | 2004-02-26 | Alex Zhu | Methods of treating involuntary facial spasms and facial wrinkles |
EP1551430A2 (en) * | 2002-10-15 | 2005-07-13 | Allergan, Inc. | Botulinum toxin dental therapies and procedures |
US7238357B2 (en) * | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
JP2007528352A (ja) * | 2003-03-06 | 2007-10-11 | ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド | 洞炎に関連する慢性の顔面痛および頭痛のボツリヌス毒素での治療 |
US7396535B2 (en) * | 2003-04-25 | 2008-07-08 | Ackerman Alan H | Therapy for obsessive compulsive head banging |
US7390496B2 (en) * | 2003-04-25 | 2008-06-24 | Allergan, Inc. | Therapeutic treatments for repetitive hand washing |
US7393538B2 (en) * | 2003-04-25 | 2008-07-01 | Ackerman Alan H | Clostridial toxin treatment for dermatillomania |
US7422753B2 (en) * | 2003-04-25 | 2008-09-09 | Allergan, Inc. | Methods for treating trichotillomania |
US7393537B2 (en) * | 2003-04-25 | 2008-07-01 | Allergan, Inc. | Botulinum toxin for treatment of obsessive compulsive finger biting disorder |
US6838434B2 (en) * | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
US20050013850A1 (en) * | 2003-07-15 | 2005-01-20 | Caers Jan K. | Device to assist hyperhydrosis therapy |
US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8617572B2 (en) | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8609113B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8609112B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
US8048423B2 (en) * | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US8871224B2 (en) | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
US20050148935A1 (en) * | 2003-12-29 | 2005-07-07 | Rozalina Dimitrova | Botulinum toxin injection guide |
US7270287B2 (en) * | 2004-01-06 | 2007-09-18 | Allergan, Inc. | Botulinum toxin treatment for kinesia |
US6974579B2 (en) * | 2004-01-08 | 2005-12-13 | Allergan, Inc. | Methods for treating vascular disorders |
US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US20050191321A1 (en) * | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US20050220821A1 (en) * | 2004-03-31 | 2005-10-06 | Allergan, Inc. | Pressure sore treatment |
US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
WO2005110417A1 (en) * | 2004-05-07 | 2005-11-24 | Phytotox Limited | Phycotoxins and uses thereof |
WO2005110418A2 (en) * | 2004-05-07 | 2005-11-24 | Phytotox Limited | Transdermal administration of phycotoxins |
US6991789B2 (en) * | 2004-06-29 | 2006-01-31 | Allergas, Inc. | Methods of modulating intracellular degradation rates of toxins |
US7922983B2 (en) * | 2005-07-28 | 2011-04-12 | Kimberly-Clark Worldwide, Inc. | Sterilization wrap with additional strength sheet |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
US20060024794A1 (en) * | 2004-07-30 | 2006-02-02 | Shengwen Li | Novel methods for production of di-chain botulinum toxin |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
AU2005279741B2 (en) | 2004-09-01 | 2011-10-06 | Allergan, Inc. | Degradable clostridial toxins |
US7179474B2 (en) * | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
US7429386B2 (en) * | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
US20060073208A1 (en) * | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
US7897147B2 (en) * | 2004-10-20 | 2011-03-01 | Allergan, Inc. | Treatment of premenstrual disorders |
US7749515B2 (en) | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
ES2420430T3 (es) | 2005-03-03 | 2013-08-23 | Allergan, Inc. | Sistema libre de productos de origen animal y procedimiento de purificación de una toxina botulínica |
AU2006227816B2 (en) | 2005-03-15 | 2012-04-05 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
AU2006340711C1 (en) | 2005-04-05 | 2013-02-07 | Allergan, Inc. | Clostridial toxin activity assays |
US7419675B2 (en) * | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
US20060269574A1 (en) * | 2005-05-31 | 2006-11-30 | De Beer Johann F | Method of repairing tendons by surgery |
WO2006129171A2 (en) * | 2005-05-31 | 2006-12-07 | Polydoor Emile Huijsmans | Method and medical package for repairing tendons by surgery |
US8105611B2 (en) | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
US7910116B2 (en) * | 2005-08-24 | 2011-03-22 | Allergan, Inc. | Use of a botulinum toxin to improve gastric emptying and/or to treat GERD |
US7824694B2 (en) * | 2006-01-12 | 2010-11-02 | Allergan, Inc. | Methods for enhancing therapeutic effects of a neurotoxin |
US20070178121A1 (en) * | 2006-01-27 | 2007-08-02 | Allergan, Inc. | Methods for enhancing skin treatments |
US7794386B2 (en) | 2006-03-15 | 2010-09-14 | Allergan, Inc. | Methods for facilitating weight loss |
US7811586B2 (en) * | 2006-05-02 | 2010-10-12 | Allergan, Inc. | Methods for alleviating testicular pain |
CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
US9061025B2 (en) * | 2006-08-31 | 2015-06-23 | Allergan, Inc. | Methods for selecting headache patients responsive to botulinum toxin therapy |
US20080092910A1 (en) * | 2006-10-18 | 2008-04-24 | Allergan, Inc. | Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures |
US20080113051A1 (en) * | 2006-11-13 | 2008-05-15 | Allergan, Inc. | Methods for alleviating tattoo pain |
ES2441961T3 (es) | 2007-02-15 | 2014-02-07 | Allergan, Inc. | Composiciones de toxina botulínica y métodos |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
US8617571B2 (en) | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
ES2356883B1 (es) * | 2008-07-24 | 2012-02-22 | Bcn Peptides, S.A. | Composición para el tratamiento del dolor y/o la inflamación. |
US20100028385A1 (en) * | 2008-08-04 | 2010-02-04 | Allergan, Inc. | Treatment of excess cerumen secretion |
JP5688031B2 (ja) | 2009-01-07 | 2015-03-25 | ロバート ジョン ペトレラ, | ヒアルロン酸およびボツリヌス毒素を使用する軟組織傷害の治療 |
CA2754423A1 (en) | 2009-03-06 | 2010-09-10 | Allergan, Inc. | Clostridial toxin to improve ejaculate |
EP2480250B1 (en) | 2009-09-24 | 2014-04-16 | Allergan, Inc. | Compositions comprising botulinum toxin A or B for use in the treatment of osteoporosis |
JP2011157331A (ja) * | 2010-02-03 | 2011-08-18 | Chemo-Sero-Therapeutic Research Inst | 高用量投与が可能なボツリヌス毒素製剤 |
WO2012103415A1 (en) | 2011-01-28 | 2012-08-02 | Allergan, Inc. | Dosage regimen for the treatment of multiple disorders with botulinum toxins |
US8697090B2 (en) | 2011-05-05 | 2014-04-15 | Allergan, Inc. | Method of treating persistent genital arousal disorder with a neurotoxin |
AU2012282873B2 (en) | 2011-07-08 | 2016-03-31 | Allergan, Inc. | Method for treatment of autonomic nervous system disorders |
US8992941B2 (en) | 2011-07-08 | 2015-03-31 | Allergan, Inc. | Method for treatment of esophageal spasm |
CN103813802A (zh) | 2011-07-14 | 2014-05-21 | 阿勒根公司 | 用于治疗与性活动相关的失禁的方法 |
WO2013012457A1 (en) * | 2011-07-20 | 2013-01-24 | Mcginley Joseph C M D Ph D | Method of treating and confirming diagnosis of exertional compartment syndrome |
US9226954B2 (en) | 2011-07-20 | 2016-01-05 | Joseph C. McGinley | Method for treating and confirming diagnosis of exertional compartment syndrome |
CN103702681A (zh) | 2011-07-20 | 2014-04-02 | 阿勒根公司 | 用于治疗脂肪沉积的方法 |
ES2424294B1 (es) | 2012-03-22 | 2014-07-21 | Lipotec, S.A. | Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas |
EP2836193B1 (en) | 2012-04-13 | 2018-01-31 | Lubrizol Advanced Materials, Inc. | Compounds which inhibit neuronal exocytosis (ii) |
EP2649983A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (II) |
EP2649985A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (III) |
EP2649984A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis |
US9138194B1 (en) | 2012-06-27 | 2015-09-22 | Joseph McGinley | Apparatus for use to replicate symptoms associated with vascular obstruction secondary to vascular compression |
US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
ES2612237T3 (es) | 2013-03-22 | 2017-05-12 | Lipotec, S.A. | Exopolisacárido para el tratamiento y/o cuidado de la piel, membranas de mucosas y/o uñas |
GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
US10058471B2 (en) * | 2014-02-21 | 2018-08-28 | William M. Vaughan | System and method of using hyperbaric oxygen therapy for treating concussive symptoms and musculoskeletal injuries and for pre-treatment to prevent damage from injuries |
EP3154572A1 (en) * | 2014-06-13 | 2017-04-19 | Merz Pharma GmbH & Co. KGaA | Novel uses of recombinant clostridial neurotoxins with decreased duration of effect |
US20170119863A1 (en) * | 2014-06-13 | 2017-05-04 | Merz Pharma Gmbh & Co. Kgaa | Novel uses of recombinant clostridial neurotoxins with decreased duration of effect |
US10647750B2 (en) | 2015-01-09 | 2020-05-12 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
CN105567739B (zh) * | 2016-02-04 | 2019-07-12 | 郑州可尔利尔生物科技有限公司 | 病毒载体颗粒及其构建方法和应用 |
CA3018018A1 (en) * | 2016-03-25 | 2017-09-28 | Ipsen Biopharm Limited | Collecting physical therapy information to enhance treatment efficacy of botulinum toxin |
GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
US20210277071A1 (en) | 2016-09-29 | 2021-09-09 | Ipsen Biopharm Limited | Hybrid neurotoxins |
WO2018106339A1 (en) * | 2016-12-06 | 2018-06-14 | Bonti, Inc. | Botulinum neurotoxins for use in tendon repair surgery |
CA3057304A1 (en) * | 2017-03-22 | 2018-09-27 | Bonti, Inc. | Botulinum neurotoxins for treating traumatic injuries |
EP4137149A1 (en) * | 2017-04-21 | 2023-02-22 | Bonti, Inc. | Initiating neurotoxin treatments |
EP3470054B1 (en) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
JP7186228B2 (ja) | 2018-02-26 | 2022-12-08 | イプセン バイオファーム リミテッド | 非細胞毒性プロテアーゼの注入を案内するための超音波の使用 |
EP3849585A1 (en) * | 2018-09-13 | 2021-07-21 | Allergan, Inc. | Methods for treatment of masseter muscle hypertrophy |
EP3825689A3 (en) | 2018-11-29 | 2021-09-15 | Hugel Inc. | A cell-based method for determining an activity of botulinum toxin |
US20220096609A1 (en) * | 2019-02-06 | 2022-03-31 | Allergan, Inc. | Combination therapy using clostridial toxin derivative and at least one chemical depolarizing agent |
CN110710494B (zh) * | 2019-10-20 | 2021-06-11 | 宋凯 | 一种眼睛王蛇毒液安全取出装置 |
JP2022040051A (ja) | 2020-08-27 | 2022-03-10 | ユニテックフーズ株式会社 | 筋損傷回復促進用組成物 |
GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
WO2024069191A1 (en) | 2022-09-30 | 2024-04-04 | Ipsen Biopharm Limited | Clostridial neurotoxin for use in a treatment of bladder pain syndrome |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0679090A1 (en) | 1993-01-15 | 1995-11-02 | Interactive Biologics Associates | Method for treating myofascial pain syndrome |
CA2164626C (en) * | 1993-06-10 | 2004-11-23 | K. Roger Aoki | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
EP0735820B1 (en) | 1993-12-22 | 1999-06-23 | Zeneca Limited | Herbicidal diphenyl ether and nitrogen solution compositions and method |
EP0737074B1 (en) * | 1993-12-28 | 2001-08-01 | Allergan Sales, Inc. | Botulinum toxins for treating hyperhydrosis |
US6203794B1 (en) | 1994-05-31 | 2001-03-20 | Allergan Sales, Inc. | Modification of clostridial toxins for use as transport proteins |
US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
US6063768A (en) * | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
GB9818548D0 (en) * | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
AU1706400A (en) * | 1998-10-27 | 2000-05-15 | Mayo Foundation For Medical Education And Research | Methods for enhancing wound healing |
US7138127B1 (en) * | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
NZ520201A (en) * | 2000-02-08 | 2004-04-30 | Allergan Inc | Botulinum toxin pharmaceutical compositions comprising a polysaccharide |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6423319B1 (en) * | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
DE10131388B4 (de) * | 2001-06-28 | 2004-07-08 | Infineon Technologies Ag | Integrierter dynamischer Speicher und Verfahren zum Betrieb desselben |
-
2000
- 2000-10-04 US US09/678,189 patent/US6423319B1/en not_active Expired - Lifetime
-
2001
- 2001-08-31 CA CA002424242A patent/CA2424242C/en not_active Expired - Lifetime
- 2001-08-31 DK DK01966482.0T patent/DK1322324T3/da active
- 2001-08-31 JP JP2002532249A patent/JP2004518632A/ja active Pending
- 2001-08-31 AU AU8699101A patent/AU8699101A/xx active Pending
- 2001-08-31 KR KR1020037004676A patent/KR100873819B1/ko active IP Right Grant
- 2001-08-31 ES ES01966482T patent/ES2348862T3/es not_active Expired - Lifetime
- 2001-08-31 EP EP10150415A patent/EP2174662A3/en not_active Withdrawn
- 2001-08-31 WO PCT/US2001/027193 patent/WO2002028425A2/en active IP Right Grant
- 2001-08-31 BR BR0114440-5A patent/BR0114440A/pt not_active IP Right Cessation
- 2001-08-31 AT AT01966482T patent/ATE477816T1/de not_active IP Right Cessation
- 2001-08-31 CN CN018199461A patent/CN1658897A/zh active Pending
- 2001-08-31 DE DE60142839T patent/DE60142839D1/de not_active Expired - Lifetime
- 2001-08-31 NZ NZ524793A patent/NZ524793A/en not_active IP Right Cessation
- 2001-08-31 EP EP01966482A patent/EP1322324B1/en not_active Revoked
- 2001-08-31 AU AU2001286991A patent/AU2001286991B2/en not_active Ceased
- 2001-08-31 CN CN2010106210202A patent/CN102078597A/zh active Pending
- 2001-08-31 MX MXPA03002576A patent/MXPA03002576A/es active IP Right Grant
- 2001-09-07 TW TW090122250A patent/TWI292713B/zh not_active IP Right Cessation
-
2002
- 2002-05-23 US US10/155,925 patent/US6955813B2/en not_active Expired - Lifetime
-
2004
- 2004-11-03 US US10/981,212 patent/US7108857B2/en not_active Expired - Lifetime
-
2006
- 2006-08-22 US US11/507,708 patent/US7468188B2/en not_active Expired - Fee Related
-
2012
- 2012-07-27 JP JP2012166469A patent/JP2012229263A/ja active Pending
Non-Patent Citations (1)
Title |
---|
British Medical Journal, Vol. 319, No. 7228, pp. 161-165(2000년 1월 15일)* |
Also Published As
Publication number | Publication date |
---|---|
DK1322324T3 (da) | 2010-11-01 |
CA2424242C (en) | 2007-08-07 |
CA2424242A1 (en) | 2002-04-11 |
MXPA03002576A (es) | 2004-04-20 |
EP1322324B1 (en) | 2010-08-18 |
US7108857B2 (en) | 2006-09-19 |
US6423319B1 (en) | 2002-07-23 |
US7468188B2 (en) | 2008-12-23 |
KR20030043981A (ko) | 2003-06-02 |
CN102078597A (zh) | 2011-06-01 |
TWI292713B (en) | 2008-01-21 |
US20050281846A1 (en) | 2005-12-22 |
WO2002028425A3 (en) | 2003-02-27 |
WO2002028425A2 (en) | 2002-04-11 |
ATE477816T1 (de) | 2010-09-15 |
BR0114440A (pt) | 2004-06-15 |
EP1322324A2 (en) | 2003-07-02 |
NZ524793A (en) | 2005-09-30 |
JP2012229263A (ja) | 2012-11-22 |
US20020192240A1 (en) | 2002-12-19 |
AU8699101A (en) | 2002-04-15 |
EP2174662A2 (en) | 2010-04-14 |
JP2004518632A (ja) | 2004-06-24 |
US20070128227A1 (en) | 2007-06-07 |
CN1658897A (zh) | 2005-08-24 |
EP2174662A3 (en) | 2010-06-30 |
AU2001286991B2 (en) | 2005-05-19 |
ES2348862T3 (es) | 2010-12-16 |
DE60142839D1 (de) | 2010-09-30 |
US6955813B2 (en) | 2005-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100873819B1 (ko) | 근육 손상의 처치방법 | |
US7723480B2 (en) | Leucine-based motif and clostridial neurotoxins | |
RU2748653C2 (ru) | Жидкая композиция, содержащая ботулотоксин и стабилизирующий агент, и способ её получения | |
AU2001286991A1 (en) | Methods for treating muscle injuries | |
JP4037652B2 (ja) | 神経毒を含む痛み処置製剤 | |
CA2632696A1 (en) | Modified clostridial neurotoxins with altered biological persistence | |
MX2012002378A (es) | Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada. | |
KR20070057862A (ko) | 조직 치유에 사용하기 위한 클로스트리디움 신경독 | |
US20170189500A1 (en) | Use of recombinant clostridial neurotoxins for the treatment of patients having certain muscle-related disorders | |
KR102063475B1 (ko) | 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
S901 | Examination by remand of revocation | ||
E902 | Notification of reason for refusal | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121123 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131122 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20141121 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20151123 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20161124 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20171127 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20181123 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20191127 Year of fee payment: 12 |